Skip to main content
SpringerLink
Log in
Book cover

Antiviral Chemotherapy 5 pp 23–27Cite as

Famciclovir Update

Chronic Hepatitis B

  • Chapter

  • 202 Accesses

Part of the book series: Advances in Experimental Medicine and Biology ((AEMB,volume 458))

Abstract

Famciclovir is the well-absorbed (77% bioavailability) oral formulation of penci-clovir. It was first licensed in 19941 and since then has been approved in a number of countries, including the United States, for the treatment of acute herpes zoster, acute recurrent and primary genital herpes, and suppression of genital herpes recurrences. In addition, Denavir, a topical formulation of penciclovir, has been approved for treatment of herpes labialis cold sores. Famciclovir and the intravenous formulation, penciclovir, have recently been granted regulatory approval in Europe for treatment of herpesvirus (i.e. varicella zoster virus, herpes simplex virus) infections in immunocompromised hosts.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   129.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD   169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Pue MA & Benet LZ Pharmacokinetics of famciclovir in man. Antiviral Chem. Chemother. 1993; 4(Suppl 1): 47–55.

    CAS  Google Scholar 

  2. Shaw T, Amor P, Civitico G, Boyd M, Locarnini S. In vitro antiviral activity of penciclovir, a novel purine nucleoside, against duck hepatitis B virus. Antimicrob Agents Chemother. 1994; 38: 719–723.

    Article  PubMed  CAS  Google Scholar 

  3. Tsiquaye KN, Slomka MJ, Maung M. Oral famciclovir against duck hepatitis B virus replication in hepatic and nonhepatic tissues of ducklings infected in ovo. J Med Virol. 1994; 42: 306–310.

    Article  PubMed  CAS  Google Scholar 

  4. Tsiquaye KN, Sutton D, Maung M, Boyd MR. Antiviral activities and pharmacokinetics of penciclovir and famciclovir in Pekin ducks chronically infected with duck hepatitis B virus. Antiviral Chem. Chemother. 1996; 7(3): 153–159.

    CAS  Google Scholar 

  5. Dannaoui E, Trepo C, Zoulim F. Inhibitory effect of penciclovir-triphosphate on duck hepatitis B virus reverse transcription. Antiviral Chem Chemother. 1997; 8(1): 38–46.

    CAS  Google Scholar 

  6. Shaw T, Mok S, Locarnini S. Inhibition of hepatitis B virus DNA Polymerase by enantiomers of penciclovir Triphosphate and metabolic basis for selective inhibition of HBV replication by penciclovir. Hepa-tology. 1996; 24(5): 996–1002.

    CAS  Google Scholar 

  7. Lin E, Luscombe C, Wang Y, et al. The Guanine Nucleoside Analog Penciclovir Is Active against Chronic Duck Hepatitis B Virus Infection In Vivo. Antimicrobial Agents Chemother. 1996; 40(2): 413–418.

    CAS  Google Scholar 

  8. Main J, Brown J, Karayiannis P, Georgiou P, Boyd M, Prince W, Thomas H. A double-blind, placebo-controlled study to assess the effect of famciclovir on virus replication in patients with chronic hepatitis B virus infection. (Poster P1C1/38). J Hepatol. Suppl 1994; S32A.

    Google Scholar 

  9. Trepo C, Jezek P, Atkinson GF, Boon RJ. Efficacy of famciclovir in chronic hepatitis B: results of a dose finding study. Hepatology. 1996; 24(Suppl 4, Pt 2): 188A (Abstract 247).

    Google Scholar 

  10. Trepo C, Jezek P, Atkinson GF, Boon RJ. Long term efficacy of famciclovir (FCV) in chronic hepatitis B: results of a Phase IIB study. J Hepatol. 1997; 26(Suppl 1): 74 (Abstract WP3/22).

    Google Scholar 

  11. Lok ASF. Treatment of chronic hepatitis B. J Vir Hepatitis. 1994; 1: 105–124.

    Article  CAS  Google Scholar 

  12. Böker KH, Ringe B, Krü ger M, Pichlmayr R, Manns MP. Prostaglandin E plus famciclovir — a new concept for the treatment of severe hepatitis B after liver transplantation. Transplantation. 1994; 57: 1706–1708.

    PubMed  Google Scholar 

  13. Neuhaus P, Manns M, Atkinson G. Safety and efficacy of Famciclovir for the treatment of recurrent Hepatitis B in liver transplant recipients. Hepatology. 1997; 26(4, Pt. 2): 260a.

    Google Scholar 

  14. Aye TT, Bartholomeusz A, Shaw T, Bowden S, Breschkin A, McMillan J, et al. Hepatitis B virus polym-erase mutations during antiviral therapy in a patient following liver transplantation. J Hepatol. 1997; 26(5): 1148–1153.

    Article  PubMed  CAS  Google Scholar 

  15. Bartholomew, M, Jansen R, Jeffers, L et al. Hepatitis-B-virus resistance to lamivudine given for recurrent infection after orthotopic liver transplantation. Lancet 1997; 349: 20–22.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. SmithKline Beecham Pharmaceuticals, 1250 South Collegeville Road, Collegeville, Pennsylvania, 19426-0989, USA

    Clarence L. Young

Authors
  1. Clarence L. Young
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Macfarlane Burnet Centre for Medical Research, Fairfield, Victoria, Australia

    John Mills

  2. University of California, San Francisco, San Francisco, California, USA

    Paul A. Volberding

  3. University of Washington, Seattle, Washington, USA

    Lawrence Corey

Rights and permissions

Reprints and permissions

Copyright information

© 1999 Springer Science+Business Media New York

About this chapter

Cite this chapter

Young, C.L. (1999). Famciclovir Update. In: Mills, J., Volberding, P.A., Corey, L. (eds) Antiviral Chemotherapy 5. Advances in Experimental Medicine and Biology, vol 458. Springer, Boston, MA. https://doi.org/10.1007/978-1-4615-4743-3_3

Download citation

  • DOI: https://doi.org/10.1007/978-1-4615-4743-3_3

  • Publisher Name: Springer, Boston, MA

  • Print ISBN: 978-1-4613-7150-2

  • Online ISBN: 978-1-4615-4743-3

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation